ARUP, ASI in Pathology Collaboration
News Nov 23, 2016
Applied Spectral Imaging (ASI) announced that they have entered a collaboration with ARUP Laboratories to facilitate the development and commercialization of advanced digital pathology solutions enhancing workflow efficiencies and simplifying the management and accessibility of clinical data.
This collaboration will bring to pathology, cytogenetics, and research labs, novel image quality and robust analysis algorithms that resolve the bottleneck of image analysis. The developed imaging platform will also transform the way pathologists deliver professional services from remote locations.
“ASI is proud to partner with ARUP Laboratories, a national reference laboratory and a worldwide leader in innovative laboratory research and development. With the professional consultancy and expertise of ARUP, throughout the development of our next-version imaging platform, we will be offering our wide customer base, an imaging solution that best supports their FISH and brightfield workflows,” said Limor Shiposh, chief executive officer of ASI. “This collaboration aligns the shared mission of both organizations: to improve the lives of patients worldwide by optimizing the scanning process to save valuable time and providing superior image quality, accurate image analysis, and enhanced access to data management and reporting tools,” Mrs. Shiposh added.
“The collaboration with ASI will provide state of the art pathology practice at ARUP and its delivery to ARUP’s clients,” said Dr. Mohamed Salama, chief of Hematopathology at ARUP Laboratories and professor of pathology at the University of Utah. “ARUP’s increasing pathology sample volumes require advanced workflow efficiencies, as well as creative data management and accessibility solutions. These collaboratively developed novel tools will enable improved efficiency and enhance accuracy. ARUP is one of the pioneers in early digital pathology adoption and is always seeking to leverage the use of technology with commitment to improved patient care.”
Story from Applied Spectral Imaging. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
While a closely-related compound did not show any senolytic activity, Azithromycin and Roxithromycin (two clinically-approved antibiotics) induced aerobic glycolysis and autophagy in human fibroblast cell lines. The findings have significant implications for alleviating ageing-associated diseases.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019